14 pág.

Pré-visualização | Página 5 de 5
Dahlöf B • et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366:895, 2005 Sep 10-16 [PMID:16154016] Fisher M, Blackwell J, Saseen J: Clinical inquiries. What is the best way to identify patients • with white-coat hypertension? J Fam Pract 54:549, 2005 [PMID:15939009] Kaplan N: Systemic hypertension: Mechanisms and diagnosis, in • Braunwald’s Heart Disease, 7th ed, D Zipes et al. (eds). Philadelphia, Saunders, 2005 O’Brien E • et al.: Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British hypertension society. BMJ 320:1128, 2000 [PMID:10775227] Sacks FM • et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344:3, 2001 [PMID:11136953] van den Born BJ • et al.: Value of routine funduscopy in patients with hypertension: systematic review. BMJ 331:, 2005 [PMID:16002881] White WB: Update on the drug treatment of hypertension in patients with cardiovascular • disease. Am J Med 118:695, 2005 [PMID:15989899] Williams B: Recent hypertension trials: implications and controversies. • J Am Coll Cardiol 45:813, 2005 [PMID:15766813] Dicas Nas pessoas com mais de 50 anos de idade, a PAS de mais de 140 mmHg é um fator de risco • mais importante para a doença cardiovascular do que a PAD.